HRTX - Heron Therapeutics' Non-Opioid Post-Operative Pain Drug Approved For Use In Additional Orthopedic Soft Tissue Procedures - FDA Gives Nod | Benzinga
The FDA has approved Heron Therapeutics Inc’s (NASDAQ:HRTX) supplemental New Drug Application for Zynrelef (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures, including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
Zynrelef was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
This expanded indication for Zynrelef will now cover an estimated 13 million procedures annually, an ...